That bumps up the previous goal of the end of July.
Biden announced that two major pharmaceutical companies will work together to "expand the production" of the Johnson & Johnson vaccine.
Increasing daily vaccine doses to 3 million would boost GDP by 1% and prevent a total of about 2 million new COVID-19 cases in 2021.
The global orphan drugs market size reached US$ 129 Billion in 2019.Orphan drugs refer to medications that are intended for diagnosing, preventing and treating rare, life-threatening diseases or disorders.As they traditionally had a limited market, very few pharmaceutical companies pursued research into these products.However, the growing number of rare diseases lacking treatment, along with improving access to healthcare and spending capacity of individuals, has led to a significant rise in the demand for orphan drugs.Get a PDF sample of this report for more detailed market insights: https://www.imarcgroup.com/orphan-drugs-market/requestsampleAt present, incentives for drug development provided by government authorities in various countries are encouraging pharmaceutical companies to develop orphan drugs.For instance, the United States Food and Drug Administration (USFDA) offers benefits such as fast-track approval, protocol assistance, waiver of fees and marketing exclusivity to manufacturers, facilitating the development and commercialization of diagnostic tools and treatments devoted to rare diseases.Furthermore, there has been a rise in the development of orphan biological drugs that can prevent or treat various forms of cancer, tumors and blood disorders, which, in turn, is contributing to the market growth.
CEO Stanley Erck said Novavax's COVID-19 vaccine could be authorized in the UK first before the FDA gives it emergency-use authorization.
Henceforth, phage therapy is the therapeutic use of lytic bacteriophages for treating pathogenic bacterial infections.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=72961Key Drivers of Global Bacteriophages Therapy MarketThere is an increase in prevalence of foodborne diseases that are caused due to food spoilage.Moreover, children under the age of 5 years carry 40% of foodborne disease burden, with 125,000 deaths every year.For instance, in January 2019, the U.S. Food and Drug Administration accepted an Investigational New Drug application by physician-scientists at the University of California San Diego School of Medicine for conducting the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.The planned trial was decided to be conducted in collaboration with AmpliPhi Biosciences Corporation, a San Diego-based biotechnology company.Request a Sample of Bacteriophages Therapy Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=72961Key Restraints of Global Bacteriophages Therapy MarketHigh cost of bacteriophages therapy is one of the prime factors restraining the growth of the global bacteriophage therapy market.Thus, lack of skilled professionals can hamper the growth of the bacteriophages therapy market.Strategic Developments and Emerging Economies to Offer Attractive OpportunitiesCompanies operating in the bacteriophages therapy market are focusing on meeting the needs of medical communities and patient population by developing novel therapies.Several players are also investing in developing advanced bacteriophage platforms.In June 2016, EnBiotix, Inc., a product-focused bioengineering company, announced collaboration with the Mayo Foundation for Medical Education and Research (MFMER)to continue he development of the company’s drug candidate, EPP-001, an engineered bacteriophage product to deliver biofilm dispersing enzymes to treat Staphylococcus aureus (S. aureus) infections in prosthetic joints.Emerging economies provide lucrative opportunities in the bacteriophage therapy market, as there is an increase in the number of patient population and initiatives by governments in the health care sectorRequest for Analysis of COVID19 Impact on Bacteriophages Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19_id=72961North America to Hold a Major Share of Global Bacteriophages Therapy MarketNorth America is expected to hold a major share of the global bacteriophages therapy market due to increasing prevalence of foodborne and other infectious diseases.
Johnson & Johnson received an Emergency Use Authorization from the FDA for its Janssen COVID-19 vaccine over the weekend. With that milestone achieved, the company is now authorized to distribute its single-shot vaccine for administration, giving the US a third vaccine product to ramp up its vaccination efforts. How will the Janssen shot be rolled out? Prior to its EUA … Continue reading
Clue, best known for its period tracking app, announced that it received clearance from the Food and Drug Administration for a digital birth control function, which it says can help users prevent pregnancy based only on the start date of a user’s period. It calculates the window where someone could get pregnant based on statistical modeling.
“It personalizes over time. So as the individual puts in their cycle day one then we’re able to personalize the window of their high risk days vs their low risk days,” Clue’s chief medical officer Lynae Brayboy told TechCrunch.
The company plans to launch its digital birth control some time this year.
Clue says that its digital birth control is 92 percent effective at preventing unwanted pregnancy...
Global Vacuum Skin Packaging Market - OverviewThe global vacuum skin packaging market is a very dynamic market and is expected to witness high growth over the forecast period.However, stringent regulations on packaging material waste and recycling expected to hinder the growth of the vacuum skin packaging market.The Food Safety Modernization Act (FSMA), enables the Food and Drug Administration (FDA) to better protect public health by strengthening the food safety system.Request a Free Sample @ https://www.marketresearchfuture.com/sample_request/2686Key Players:Bemis Company Inc. (U.S.), Berry Global Group, Inc. (U.S.), LINPAC Packaging Limited (U.K.), Amcor Ltd. (Australia), Sealed Air Corporation (U.S.), DuPont (U.S.), G. Mondini SA (Italy), and Green Packaging Material (Jiangyin) Co., Ltd. (China) are some of the prominent players at the forefront of competition in the global vacuum skin packaging market and are profiled in MRFR Analysis.Along with leadership positions in Europe and Asia, a strong presence in South America significantly improves Amcor’s customer value proposition in the flexible packaging marketplace, positioning us as a partner of choice for customers.The acquisitions strategy is focused on improving company’s long-term financial performance, enhance market positions and expand existing and complementary product lines.
Global Low-calorie RTD Beverages Market: An Overview The global low-calorie RTD beverages market is expected to register robust growth in the near future.The low-calorie RTD beverages market is driven by increasing health consciousness, growing disposable income, and rising product innovations.Today, consumers are increasingly replacing CSD drinks with products from the low-calorie RTD beverages market.Request PDF brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=65360 Global Low-calorie RTD Beverages Market: Notable Developments The Food and Drug Administration (FDA) banned the use of six different food additives in 2018.The companies operating in the low-calorier RTD beverages market will have two years to find new ingredients to replace the current ones.Global Low-calorie RTD Beverages Market: Key Trends Urbanization, busy lifestyle, and growing health consciousness are expected to drive major growth for the low-calorie RTD beverages market.
On Saturday, the US Food and Drug Administration announced that it had issued an emergency use authorization for the Johnson & Johnson COVID-19 vaccine, the third overall.The acting commissioner of FDA, Dr. Janet Woodcock said, “The authorization of this vaccine expands the availability of vaccines, the best medical prevention method for COVID-19, to help us in the fight against this pandemic, which has claimed over half a million lives in the United States.The FDA, through our open and transparent scientific review process, has now authorized three COVID-19 vaccines with the urgency called for during this pandemic, using the agency’s rigorous standards for safety, effectiveness, and manufacturing quality needed to support emergency use authorization”.The FDA also said that tests on the Janssen Biotech Inc., a vaccine was about 67% effective in preventing moderate to severe cases within 14 days after dosing and 66% effective against severe to critical cases after 28 days.Point to be noted that it takes just one shot which is more effective compared to the previous vaccines.Recipients of an emergency use authorization are required to file safety reports and inform the FDA of any serious issues, side effects, hospitalizations, or deaths as a result of their product.The FDA based its decision on a study of the Janssen vaccine on more than 39,000 people in multiple countries, including the US.It is noteworthy that the Pfizer and Moderna vaccines require 2 doses and these are 95% and 94.1% effective, respectively.
According to the report, the global smart diabetes management market was valued at ~ US$ 3.7 Bn in 2018.The smart diabetes management market is expected to expand at a CAGR of ~ 15% during the forecast period of 2019 to 2027.Smart diabetes management devices include insulin delivery and blood glucose monitoring devices.Smart diabetes management products play an important role in maintaining blood glucose levels that are vital in the treatment of diabetes, and increase patient compliance.Request a PDF Sample - https://www.transparencymarketresearch.com/sample/sample.php?flag=S_id=69717The devices segment held a major share of the smart diabetes management market in 2018.For instance, According to the World Health Organization, an estimated 1.6 million deaths were caused due to diabetes in 2014, and around 8.5% of adults had diabetes, worldwide.Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=69717Smart Diabetes Management Market: Prominent RegionsNorth America holds a major share of the global smart diabetes management market.For instance, In March 2018, Sanofi-Aventis U.S. LLC received approval from the U. S. Food and Drug Administration for Toujeo Max SoloStar.This agreement enabled the company to expand its insulin pump options for patients and healthcare providers.Purchase Smart Diabetes Management Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=69717=SThe global smart diabetes management market is moderately fragmented, with top three to four players accounting for around 40% to 50% of the global market.
"All three (vaccines) are really quite good, and people should take the one that's most available to them," Fauci said on NBC News' "Meet the Press."
The cheese recall announced earlier this month has expanded to include additional types of cheese, according to El Abuelito Cheese. Multiple brands are covered by this recall, which now includes Quesillo and Requeson products in addition to queso fresco soft cheeses. The reason for the recall is a Listeria outbreak that has caused cases in four states. Earlier this month, … Continue reading
J&J's vaccine is a single dose that can be stored in typical refrigeration, arming the US with another weapon in the fight against the pandemic.
The Food and Drug Administration’s vaccine advisers have officially recommended that Johnson & Johnson’s Janssen single-shot COVID-19 vaccine receive an Emergency Use Authorization, which will make it the first single-shot vaccination against SARS-CoV-2 in the US. With this recommendation in place, the EUA is expected to drop any time now. Unlike the Moderna and Pfizer COVID-19 vaccines currently distributed in … Continue reading
The next step is emergency use authorization by the FDA.
The FDA has allowed more flexible Pfizer COVID-19 vaccine transportation and storage rules, after the pharmaceutical company released new evidence that the drug doesn’t necessarily require the ultra-low temperatures first suggested. Pfizer announced the updated findings last week, having initially advised that the vaccine it developed with BioNTech needed to be kept at temperatures between -80ºC and -60ºC (-112ºF to … Continue reading
Transparency Market Research (TMR) has published a new report titled, ‘Inhalation and Nasal Sprays Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.According to the report, the global Inhalation & Nasal Sprays Generic Drugs market was valued at US$ 27,512.41 Mn in 2018 and is projected to expand at a CAGR of 4.80% from 2019 to 2027.OverviewInhalation and nasal spray drugs are the kind of medications employed for relieving runny, stuffy, itchy nose, sneezing, and watery eyes caused by hay infections, among others.The sale of nasal sprays and generic inhalers in expected to increase in the forecast period owing to the rise in the number of patients suffering from chronic obstructive pulmonary disease (COPD), and asthma.North America dominated the global inhalation and nasal sprays generic drugs market in 2018 and the trend is anticipated to continue during the forecast period.This was due to increase in the incidence of COPD and asthma and rising number of awareness programs initiated by governments regarding the availability of generic inhalation drugsAsia Pacific is likely to be a highly lucrative market for inhalation and nasal spray generic drugs and it is expected to expand at a high CAGR during the forecast period.Key factors driving the market in the region are presence of large population base, increasing government support, and rising incidence of respiratory disorders.Moreover, growing preferences of the population for generic drugs in order to curtail health care costs is likely to boost the growth of the inhalation and nasal spray generic drugs market in Asia Pacific Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B_id=1922Low cost involved with generic prescription drugs to Drive MarketAll generic drugs approved by the U.S. Food and Drug Administration have met the same rigid standards as the branded innovator drug and are available at extremely affordable prices.Patent expiration of a branded drug leads to competition among generic manufacturers to produce generic versions at lower prices.The rationale behind such low prices of inhalation and nasal spray generic drugs is that no R investments, advertising, marketing, and promotion are involved in the manufacture of generic drugs.
A third coronavirus vaccine by Johnson & Johnson could be approved for emergency use by the FDA by Friday, accelerating the US vaccine rollout.